3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
242
Carboplatin
135
Nivolumab
132
Gemcitabine
127
Paclitaxel
116
Cisplatin
105
Bevacizumab
95
Cyclophosphamide
93
Dexamethasone
78
Injections
75
Docetaxel
72
Pemetrexed
71
Fluorouracil
68
Capecitabine
65
Rituximab
61
Cetuximab
61
atezolizumab
60
130-nm albumin-bound paclitaxel
59
Oxaliplatin
58
Leucovorin
56
Ipilimumab
54
fludarabine
47
Lenalidomide
47
Azacitidine
40
Irinotecan
39
venetoclax
38
Fulvestrant
38
Albumin-Bound Paclitaxel
36
Prednisone
35
Trastuzumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts